Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...
Spravato has been approved since 2019 for ... by its cost and a requirement for two hours of patient observation after administration. They suggest other fast-acting antidepressants could offer ...
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...
Read more › Aid to South Africa: Mr. Trump ordered that all aid to South Africa be halted and said his administration would prioritize the resettling of white “Afrikaner refugees” into the ...
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results